Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Cerulean Announces Clinical Collaboration with AstraZeneca and the National Cancer Institute to Evaluate the Combination of LYNPARZA™ and CRLX101

Wedbush Reiterated an Outperform on Cerulean Pharma (CERU) Following 3Q

November 17, 2015 1:18 PM EST

Wedbush reiterated an Outperform rating on Cerulean Pharma (NASDAQ: CERU), and cut the price target to $9.00 (from $16.00), following the company's 3Q earnings report. CERU reported a net loss of $10.6M ($0.39/share), slightly above consensus of ($0.41).

Analyst David Nierengarten commented, "CERU reported a net... More